



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Attorney Docket No: 038602/039

In re patent application of  
Gregory PLOWMAN *et al.*

Serial No.: 09/069,228

Filed: April 27, 1998

For: DIAGNOSIS AND TREATMENT OF ALK-7 RELATED DISORDERS

Group Art Unit: 1642

Examiner: A. HOLLERAN

RECEIVED  
JUL 18 2001  
TECH CENTER 1600/2900  
#19c 7/23/01  
Bray

**AMENDMENT AND REQUEST FOR RECONSIDERATION**  
**UNDER 37 C.F.R. §1.111**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This responds to the Office Action mailed on January 12, 2001 in the above-identified application. Enclosed herewith is a Petition for a three-month extension of time to extend the time to respond to July 12, 2001, and the requisite fee. Should such a request be deficient or absent or if there are any other deficiencies, consider this paragraph such a request and authorization to charge the appropriate fee under 37 C.F.R. §§ 1.16 to 1.18 to Deposit Account No. 19-0741.

Kindly amend the application as follows:

Kindly cancel claims 38-40 without prejudice or disclaimer.

C' 36. (AMENDED) The nucleic acid molecule of Claim 35, wherein said truncated polypeptide is obtained by insertion of a hemophilus influenza hemagglutinin-tag (HA-tag) at position 230 of the amino acid sequence set forth in SEQ ID NO:2.

**REMARKS**

Claims 2-5, 9 and 23-37 are presently pending in this application. Claim 36 is amended to more clearly claim the present invention and claims 38-40 are canceled without prejudice or disclaimer. The cancellation or amendment of claims and/or claim language is done so without prejudice or disclaimer for filing in